Information Provided By: 
Fly News Breaks for January 18, 2019
IMMU
Jan 18, 2019 | 07:13 EDT
Wells Fargo analyst Jim Birchenough downgraded Immunomedics to Market Perform from Outperform and cut his price target for the shares to $18 from $44 following yesterday's Complete Response Letter from the FDA for sacituzumab govitecan in triple negative breast cancer. The CRL may suggest greater complexity of issues to address, Birchenough tells investors in a research note. He recommends taking a "wait-and-see approach" pending better visibility on specific issues and timelines.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
